Hypertension, PulmonaryPhase 3PATENT-CHILDNCT02562235
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
A Phase 3 study testing Riociguat (Adempas, BAY63-2521) in people with Hypertension, Pulmonary, run by Bayer at 16 sites in 9 countries.
Trial summary
This study was designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID in children from ≥6 to less than 18 years with pulmonary arterial hypertension (PAH) group 1. Read more about this study
- Who is it for?
- Ages 6 to 17 years
- Conditions the study is for
- Hypertension, Pulmonary
- What is being tested?
- Riociguat (Adempas, BAY63-2521)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 16 sitesin 9 countries
- Study dates
- 29 Oct 2015to 15 May 2028
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Children from 6 years to less than 18 years of age with pulmonary arterial hypertension (PAH)
- Diagnosed with PAH :
- Idiopathic (IPAH)
- Hereditable (HPAH)
- PAH associated with (APAH)
- Connective tissue disease
Show all 19Show fewer
- Congenital heart disease with shunt closure more than 6 months ago (no open shunts, confirmed by RHC no less than 4 months after surgery)
- Regardless of the type of PAH, the following findings are not exclusionary:
- --- Patent foramen ovale (PFO) and asymptomatic, isolated, ostium secundum atrial septal defect (OS-ASD) ≤ 1 cm (both confirmed by echocardiogram) and not associated with hemodynamic alterations indicative of significant shunt, e.g. Qp/Qs ratio less <1.5:1 are not exclusionary
- PAH diagnosed by right heart catheterization (RHC) at any time prior to enrolment (for patients with closed shunts - RHC no less than 4 months after surgery)
- PAH confirmed by a RHC at any time prior to start of study, with mean pulmonary artery pressure (PAPmean) ≥25 mmHg at rest, pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) ≤15 mmHg, and pulmonary vascular resistance (PVR) >240 dyn•sec•cm^-5 (i.e., ≥3.0 wood units•m^2)
- Patients must be on standard of care PAH medications, allowing Endothelin Receptor Antagonists (ERA) and/or Prostacyclin Analogues (PCA), for at least 12 weeks prior to baseline visit.
- Two groups of patients will be included:
- Prevalent: Patients currently on PAH medication (allowing ERA and/or PCA) who need additional treatment (discretion of the investigator)
- Incident: Treatment naïve patients initiated on PAH medication (allowing ERA and /or PCA) and then riociguat added once patients are stable on standard of care
- WHO functional class I-III
- Adolescent females of childbearing potential can only be included in the study if a pregnancy test is negative. Adolescent females of childbearing potential must agree to receive sexual counseling and use effective contraception as applicable. 'Effective contraception' is defined as progestogen-only hormonal contraception associated with inhibition of ovulation (implant), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), or any combination of adequate methods of birth control (e.g. condoms with hormonal contraception). Agreement to use contraception is required from the signing of the informed consent form up until 4 weeks after the last study drug administration.
- Young men must agree to use adequate contraception when sexually active.
- Written inform consent provided and if applicable child assent provided
Who cannot join
- Concomitant use of the following medications: phosphodiesterase (PDE) 5 inhibitors (such as sildenafil, tadalafil, vardenafil) and non-specific phosphodiesterase (PDE) inhibitors (theophylline, dipyridamole), nitrates or NO donors (such as amyl nitrite) in any form
- -- Pretreatment with NO donors (e.g. nitrates) within the last 2-weeks before visit 1. The use of any drug including NO acutely for testing during catheterization is not an exclusion criterion.
- Active state of hemoptysis or pulmonary hemorrhage, including those events managed by bronchial artery embolization or any history of bronchial artery embolization or massive hemoptysis within 3 months prior to screening
- Systolic blood pressure (SBP) more than 5 mmHg lower than the age-, sex- and height-adapted level of the 50th SBP percentile (NHBPEP, 2004)
- History of left-sided heart disease, including valvular disease or heart failure
- Pulmonary hypertension related to conditions other than specified in the inclusion criteria
Show all 14Show fewer
- WHO functional class IV
- Pulmonary veno-occlusive disease
- Screening aspartate transaminase (AST) and/ or alanine transaminase (ALT) more than 3 times the upper limit of normal (ULN)
- Severe restrictive lung disease
- Severe congenital abnormalities of the lung, thorax, and diaphragm
- Clinically relevant hepatic dysfunction (especially Child Pugh C)
- Renal insufficiency (estimated glomerular filtration rate <30 mL/min/1.73m^2 e.g. calculated based on Schwartz formula)
- PH associated with idiopathic interstitial pneumonia (PH-IIP)
Trial locations and contacts
16 sites in 9 countries.
16 sites in 9 countries
Japan4 sites
Aichi Children's Health and Medical Center
Ōbu, Aichi-ken, 474-8710
Keio University Hospital
Shinjuku-ku, Tokyo, 160-8582
The University of Osaka Hospital
Suita, Osaka, 565-0871
National Cerebral and Cardiovascular Center
Suita, Osaka, 565-8565
Germany3 sites
Deutsches Herzzentrum der Charité (DHZC)
Berlin, State of Berlin, 13353
Universitätsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg, 69115
Universitätsklinikum Ulm
Ulm, Baden-Wurttemberg, 89075
Hungary2 sites
Gottsegen Gyorgy Orszagos Kardiovaszkularis Intezet
Budapest, Budapest, 1096
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
Szeged, Csongrád-Csanád, 6720
Mexico2 sites
Operadora de Hospitales Angeles S. A. de C. V.
Huixquilucan, State of Mexico, 52763
Instituto Nacional de Cardiología "Ignacio Chávez"
México D.F., Mexico City, 14080
Colombia1 site
Clínica Imbanaco S.A.S
Cali, Valle del Cauca Department, 760042
Italy1 site
Azienda Ospedale-Università di Padova - UOC Cardiologia Pediatrica
Padova, Veneto, 35128
Turkey (Türkiye)1 site
Hacettepe Universitesi Tip Fakultesi
Ankara, 06230
About this study
Official title: Open-label, Individual Dose Titration Study to Evaluate Safety, Tolerability and Pharmacokinetics of Riociguat in Children From 6 to Less Than 18 Years of Age With Pulmonary Arterial Hypertension (PAH)
This study was designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID in children from ≥6 to less than 18 years with pulmonary arterial hypertension (PAH) group 1. The study design consisted of a main study part followed by an optional long-term extension part. The main treatment period consisted of two phases: titration phase up to 8 weeks and a maintenance phase up to 16 weeks.
- Conditions
- Hypertension, Pulmonary
- Being tested
- Riociguat (Adempas, BAY63-2521)
- Keywords
- Pulmonary arterial hypertension
- Medical subject headings
- Hypertension, Pulmonary, Pulmonary Arterial Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Riociguat (Adempas, BAY63-2521)Drug
For children with body-weight <50 kg at screening: body-weight adjusted dose equivalent to the exposure of (0.5 mg) 1.0 - 2.5 mg three times a day, IDT in adults treated for PAH; oral suspension. For children ≥50 kg at screening: 1.0 to 2.5 mg three times a day; oral tablet.
| Study group | Role | What they receive |
|---|---|---|
| Riociguat | Experimental | Participants with age ≥6 to <18 years received riociguat up to 2.5 mg three times a day (titration between 1.0 mg and 2.5 mg) for up to 8 weeks during the individual dose titration (IDT) phase, and followed with the last dose administered in the IDT phase for up to 16 weeks during the maintenance phase. Down-titration (up to 0.5 mg) of the dose for safety reasons was allowed at any time. Receives: Drug: Riociguat (Adempas, BAY63-2521) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Any Treatment-emergent Adverse Events
An adverse event (AE), including AE in relation to a medical device (i.e. Raumedic dosing pipette), is any untoward medical occurrence in a participant administered with a pharmaceutical product and does not necessarily have to have a causal relationship with this treatment. A serious AE (SAE) is any untoward medical occurrence that at any dose is resulting in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity. AEs occurring between start of study drug and up to 2 days after the last dose were defined as treatment-emergent AEs (TEAEs).
Measured: From start of study drug up to 2 days after the last dose of study drug in the main study part, up to 24 weeks plus/minus 5 days.
Change in Heart Rate From Baseline
Mean change in heart rate from baseline is reported.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Blood Pressure From Baseline
Mean changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline are reported.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Respiratory Rate From Baseline
Mean change in respiratory rate from baseline is reported.
Measured: Baseline and Week 24 (plus/minus 5 days)
Number of Subjects With Transitions From Baseline in Bone Age Compared to Chronological Age
X-ray of left hand was performed for each participant and bone age was determined centrally by a specialist. For each participant, the bone age was compared to the chronological age and assigned to one of the categories - "delayed", "in accordance" or "advanced", indicating the advancement or delay in the growth of the bone. Number of participants who transitioned to another category different from baseline was calculated and is reported.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Hematology Parameters (Platelets) From Baseline
Hematology parameters were collected. Parameters with a decrease or increase in the mean value compared to baseline are reported in this data set.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Hematology Parameters (Lymphocytes/Leucocytes Ratio) From Baseline
Hematology parameters were collected. Parameters with a decrease or increase in the mean value compared to baseline are reported in this data set.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Hematology Parameter (Neutrophils/Leucocytes Ratio) From Baseline
Hematology parameters were collected. Parameters with a decrease or increase in the mean value compared to baseline are reported in this data set.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Clinical Chemistry (Alanine Aminotransferase) From Baseline
Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Clinical Chemistry (Aspartate Aminotransferase) From Baseline
Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Clinical Chemistry (Sodium) From Baseline
Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Clinical Chemistry (Blood Urea Nitrogen) From Baseline
Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Clinical Chemistry (eGFR) From Baseline
Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set. eGFR = estimated glomerular filtration rate
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Clinical Chemistry (Urea) From Baseline
Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Clinical Chemistry (Gamma Glutamyl Transferase) From Baseline
Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.
Measured: Baseline and Week 24 (plus/minus 5 days)
Plasma Concentration of Riociguat at Week 0
For each participant, one blood sample was collected at one given time point. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported. W = Week.
Measured: Week 0 (30-90 minutes post-dose; 2.5-4 hours post-dose)
Plasma Concentration of Riociguat at Week 4
For each participant, one blood sample was collected at one given time point. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported.
Measured: Week 4 (pre-dose)
Plasma Concentration of Riociguat at Week 8
For each participant, one blood sample was collected at one given time point. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported.
Measured: Week 8 (pre-dose)
Plasma Concentration of BAY60-4552 at Week 0
BAY60-4552 is riociguat's active metabolite. For each participant, one blood sample was collected at one given time point and in that sample both riociguat and BAY60-4552 were measured. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported. W = Week
Measured: Week 0 (30-90 minutes post-dose; 2.5-4 hours post-dose)
Plasma Concentration of BAY60-4552 at Week 4
BAY60-4552 is riociguat's active metabolite. For each participant, one blood sample was collected at one given time point and in that sample both riociguat and BAY60-4552 were measured. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported.
Measured: Week 4 (pre-dose)
Plasma Concentration of BAY60-4552 at Week 8
BAY60-4552 is riociguat's active metabolite. For each participant, one blood sample was collected at one given time point and in that sample both riociguat and BAY60-4552 were measured. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported.
Measured: Week 8 (pre-dose)
Secondary outcomes (25)
Change in 6-minute Walking Distance From Baseline
6-minute walking distance (6MWD) is a exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. An increase in the distance walked indicates improvement in basic mobility.
Measured: Baseline and Week 24 (plus/minus 5 days)
Number of Subjects With Change in WHO Functional Class From Baseline
The World Health Organization (WHO) functional class describes how severe a patient's pulmonary hypertension (PH) symptoms are. There are four different classes - I is the mildest and IV the most severe form of PH. Number of participants per change in number of classes is reported.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in NT-proBNP From Baseline
Laboratory biomarkers N-terminal prohormone brain-type natriuretic peptide (NT-proBNP) or brain-type natriuretic peptide (BNP) were tested for the participants. When both tests were available, NT-proBNP was chosen over BNP and the same test was performed at every required visit.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in BNP From Baseline
Laboratory biomarkers N-terminal prohormone brain-type natriuretic peptide (NT-proBNP) or brain-type natriuretic peptide (BNP) were tested for the participants. When both tests were available, NT-proBNP was chosen over BNP and the same test was performed at every required visit.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Quality of Life Evaluated by SF-10 Questionnaire From Baseline
SF-10 is a parent-completed health survey for children that contains 10 questions adapted from the Child Health Questionnaire. It is scored using nom-based scoring to produce physical and psychosocial health summary measures. The possible range for the physical measure is -10.9 to 57.2 scores and the possible range for the psychosocial measure is 8.8 to 62.3 scores. Higher scores indicate more favorable functioning.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Quality of Life Evaluated by PedsQL Scale
The PedsQL Generic Core Scales were designed to measure health-related quality of life in children and adolescents. It has 4 dimensions: physical functioning, emotional functioning, social functioning and school functioning. 3 Summary Scores of PedsQL were calculated from the scales including total scale score (23 questions), physical health summary score (physical functioning, 8 questions) and psychosocial health summary score (emotional, social and school functioning, 15 questions). Responses of the questions are transformed to a 0-100 scale. Higher scores indicate better quality of life.
Measured: Baseline and Week 24 (plus/minus 5 days)
Number of Subjects With Clinical Worsening
Clinical worsening was defined as: hospitalization for right heart failure, death, lung transplantation, Pott's anastomosis and atrioseptostomy, worsening of pulmonary arterial hypertension (PAH) symptoms, which must include either an increase in World Health Organization (WHO) functional class or appearance/worsening symptoms of right heart failure and need for additional PAH therapy.
Measured: Up to Week 24 (plus/minus 5 days)
Change in Estimated Right Atrial Pressure From Baseline
Estimated right atrial pressure was measured by echocardiography.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Left Ventricular Eccentricity Index From Baseline
Left ventricular (LV) eccentricity index (EI) was measured by echocardiography and defined as the ratio of the LV anteroposterior dimension to the septolateral dimension in the parasternal short-axis window by echocardiography. The value of EI greater than 1.0 is abnormal and suggests right ventricle (RV) overload.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Pericardial Effusion From Baseline
Pericardial effusion was measured by echocardiography.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Pulmonary Artery Acceleration Time From Baseline
Pulmonary artery acceleration time was measured by echocardiography.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Right Ventricular Cardiac Index From Baseline
Right ventricle (RV) cardiac index (CI) was measured by echocardiography and calculated by dividing the cardiac output (stroke volume × heart rate) by the body surface area. The change in RV CI should not be understood solely but associated with other conditions of the participants.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Right Ventricular Cardiac Output From Baseline
Right ventricular cardiac output was measured by echocardiography.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Right Atrial Diastolic Area From Baseline
Right atrial diastolic area was measured by echocardiography.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Right Atrial Diastolic Area Index From Baseline
Right atrial (RA) diastolic area index was measured by echocardiography and calculated by dividing the RA area at end-diastole by the body surface area. The RA area index is a reflection of RA volume at end-diastole. The change in the index should not be understood solely but associated with other conditions of the participants.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Right Atrial Systolic Area From Baseline
Right atrial systolic area was measured by echocardiography.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Right Atrial Systolic Area Index From Baseline
Right atrial (RA) systolic area index was measured by echocardiography and calculated by dividing the RA area at end-systole by the body surface area. The RA area index is a reflection of RA volume at end-systole. The change in the index should not be understood solely but associated with other conditions of the participants.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Right Ventricular Fractional Area Change From Baseline
Right ventricular fractional area change was measured by echocardiography.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Right Ventricular Diastolic Area From Baseline
Right ventricular diastolic area was measured by echocardiography.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Right Ventricular Diastolic Area Index From Baseline
Right ventricular (RV) diastolic area index was measured by echocardiography and calculated by dividing the RV area at end-diastole by the body surface area. The RV area index is a reflection of RV volume at end-diastole. The change in the index should not be understood solely but associated with other conditions of the participants.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Right Ventricular Systolic Area From Baseline
Right ventricular systolic area was measured by echocardiography.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Right Ventricular Systolic Area Index From Baseline
Right ventricular (RV) systolic area index was measured by echocardiography and calculated by dividing the RV area at end-systole by the body surface area. The RV area index is a reflection of RV volume at end-systole. The change in the index should not be understood solely but associated with other conditions of the participants.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Systolic Pulmonary Artery Pressure From Baseline
Systolic pulmonary artery pressure was measured by echocardiography.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Tricuspid Annular Plane Systolic Excursion From Baseline
Tricuspid annular plane systolic excursion (TAPSE) was measured by echocardiography.
Measured: Baseline and Week 24 (plus/minus 5 days)
Change in Tricuspid Regurgitation Peak Velocity From Baseline
Tricuspid regurgitation peak velocity was measured by echocardiography.
Measured: Baseline and Week 24 (plus/minus 5 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2015 (estimated)
- Study start29 Oct 2015
- Primary completion7 Mar 2020
- Study completion15 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Hypertension, PulmonaryStudies of the same condition, open and under way.
- More trials run by BayerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bayer
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Merck Sharp & Dohme LLC
- Responsible party
- Sponsor
- Investigators
- Bayer Study Director, Study director, Bayer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02562235
- Sponsor's protocol ID
- 15681
- Other IDs
- 2014-003952-29, 2014
- Acronym
- PATENT-CHILD
- Status last verified
- Aug 2026
- First submitted
- 28 Sep 2015
- Last updated
- 23 Sep 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.